Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06988488 · ClinicalTrials.gov registry record · Phase 1

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

A Phase 1 study of Multiple Myeloma, sponsored by Celgene.

Recruiting
Registry status
Phase 1
Development phase
62
Enrollment target
20
Study locations

NCT06988488 is a Phase 1 study of Multiple Myeloma that is actively recruiting participants, run by Celgene. The registered enrollment target is 62 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06988488, a Phase 1 study of Multiple Myeloma, is actively recruiting participants, sponsored by Celgene.

RECRUITING
Registry status
Phase 1
Development phase
62 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Dexamethasone
  • DRUG Elranatamab
  • DRUG Mezigdomide

Study Locations (20)

Other

  • Universitaetsklinikum Carl Gustav Carus Dresden - Dresden
  • Universitaetsklinikum Hamburg-Eppendorf - Hamburg
  • Universitaetsklinikum Heidelberg - Heidelberg
  • Sykehusapoteket Ull - Oslo
  • Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca - Salamanca

Attikí

  • Evangelismos General Hospital of Athens - Athens
  • Alexandra General Hospital of Athens - Athens

Alabama

  • University of Alabama at Birmingham - Birmingham

Connecticut

  • Yale New Haven Hospital-Smilow Cancer Center - New Haven

New Jersey

  • Hackensack University Medical Center - Hackensack

Texas

  • University of Texas MD Anderson Cancer Center - Houston

Alberta

  • Arthur J E Child Comprehensive Cancer Centre - Calgary

British Columbia

  • Local Institution - 0026 - Vancouver

Trial Details

FieldValue
Enrollment Target 62 participants
Start Date 2025-10-07
Est. Completion 2027-06-03
Phase Phase 1

Sponsor

Celgene

308 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06988488

The ClinicalTrials.gov registry entry for NCT06988488 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (89% lower). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.

NCT06988488 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, Attikí, Alabama.

Frequently Asked Questions

What is clinical trial NCT06988488 about?

NCT06988488 is a clinical study titled "A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma". The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).

What is the current status of trial NCT06988488?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2025-10-07. Estimated completion is 2027-06-03.

What conditions does trial NCT06988488 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT06988488?

The interventions under investigation include: Dexamethasone (DRUG), Elranatamab (DRUG), Mezigdomide (DRUG).

Who is sponsoring clinical trial NCT06988488?

This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06988488 being conducted?

This trial has 20 study locations across Alabama, Connecticut, New Jersey, Texas, Alberta. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.